Email for further information: firstname.lastname@example.org
February 2015. MRC funding for MASTERPLANS consortium
The Manchester University led MASTERPLANS consortium, of which Aeirtec is a member, have been awarded a £4.2m fund by the UK Medical Research Council (MRC) for stratification of patients with system lupus erythematosus (SLE) according to treatment response. Aeirtec will provide high sensitivity multiplex analysis of markers in patients' samples to identify marker patterns within the stratification.
July 2014 Aeirtec receives funding from the Tenovus Cancer Care charity.
Aeirtec have recieved funding from Tenovus Cancer Care within a collborative project to examine immune/inflammatory markers in cancer patients.
July 2015. MRC and EPSRC funding for Manchester Molecular Pathology Node
To support molecular pathology, the MRC and EPSRC have supported six nodes led by the universities of Edinburgh, Glasgow, Leicester, Manchester, Newcastle and Nottingham. Each node brings researchers, clinicians and industry together to develop molecular diagnostic tools, to enable disease stratification. Aeirtec is a member of the Manchester-led node and the focus of this node is on rheumatoid arthritis, psoriasis and lupus.
October 2016. BBSRC funding.
Aeirtec and Manchester University have received funding from BBSRC for studies toward innovation in immunoassay technology.
November 2016. Aeirtec and Manchester University present at the ARC.
Aeirtec and Manchester University will present data from marker multiplex profiling in SLE at the Amercian College of Rheumatology (ACR) meeting 11th -16th November in Washington DC. Title: High Sensitivity Multiplex ELISA Reveals Cytokine Expression Heterogeneity in Active SLE.
February 2017. Aeirtec develops 'Universal Immunoassay Buffer'
Aeirtec has developed a universal immunoassay buffer for use in capture and detection stages, improving sensitivity and minimising both nonspecific binding and heterophylic antibody activity.